Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 122,516 shares, a decline of 15.2% from the January 29th total of 144,490 shares. Currently, 7.7% of the shares of the company are sold short. Based on an average daily trading volume, of 108,559 shares, the short-interest ratio is presently 1.1 days. Based on an average daily trading volume, of 108,559 shares, the short-interest ratio is presently 1.1 days. Currently, 7.7% of the shares of the company are sold short.

Cardio Diagnostics Price Performance

Shares of CDIO opened at $4.74 on Wednesday. The company has a 50-day moving average of $2.42 and a two-hundred day moving average of $3.26. The stock has a market cap of $8.67 million, a price-to-earnings ratio of -1.27 and a beta of 2.28. Cardio Diagnostics has a one year low of $0.97 and a one year high of $17.39.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Cardio Diagnostics

A hedge fund recently raised its stake in Cardio Diagnostics stock. DRW Securities LLC grew its holdings in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,463 shares of the company’s stock after purchasing an additional 22,298 shares during the quarter. DRW Securities LLC owned about 2.21% of Cardio Diagnostics worth $110,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.